VRP Verona Pharma Plc

                               Verona Pharma plc

                      ("Verona Pharma" or the "Company")

                               Notice of Results

05 May 2015, Cardiff - Verona Pharma plc (AIM: VRP), the drug development
company focused on first-in-class medicines to treat respiratory diseases,
expects to announce its preliminary results for the year ended 31 December 2014
on Tuesday 12 May 2015.

                                    -Ends-

For further information please contact:

Verona Pharma plc                               Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer

FTI Consulting                                  Tel: +44 (0)20 3727 1000
Julia Phillips / Simon Conway


Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company
focused on the development of innovative prescription medicines to treat
respiratory diseases with significant unmet medical needs, such as chronic
obstructive pulmonary disease (COPD), asthma and cystic fibrosis.

Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase
II trials as a nebulised treatment for acute exacerbations of COPD in the
hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and
therefore has both bronchodilator and anti-inflammatory effects, which are
essential to the improvement of patients with COPD and asthma.

Verona Pharma is also building a broader portfolio of RPL554-containing
products to maximise its benefit to patients and its value. This includes the
very significant markets for COPD and asthma maintenance therapy. The Company
is also exploring the potential of the drug in different diseases, such as
cystic fibrosis, where it is in pre-clinical testing and has recently received
a Venture and Innovation Award from the Cystic Fibrosis Trust.